Serum MiRNA as Predictive and Prognosis Biomarker in Advanced Stage Non-small Cell Lung Cancer in Indonesia

• Published in: Zhongguo fei ai za zhi Vol. 23; no. 5; pp. 321 - 332
• Main Authors: Hanafi, Arif R, Jayusman, Achmad M, Alfasunu, Serafim, Sadewa, Ahmad H, Pramono, Dibyo, Heriyanto, Didik S, Haryana, Sofia M
• Format: Journal Article
• Language: Chinese; English
• Published: China Chinese Anti-Cancer Association Chinese Antituberculosis Association 20.05.2020; 中国肺癌杂志编辑部; Chinese Anti-Cancer Association; Chinese Antituberculosis Association
• Subjects: Adult; advanced stage nsclc; Aged; Aged, 80 and over; Biomarkers; Biomarkers, Tumor - blood; Biomarkers, Tumor - genetics; Carcinoma, Non-Small-Cell Lung - blood; Carcinoma, Non-Small-Cell Lung - diagnosis; Carcinoma, Non-Small-Cell Lung - mortality; Cell cycle; Cell growth; Clinical Research; Female; Humans; Indonesia; Laboratories; Lung cancer; Lung Neoplasms - blood; Lung Neoplasms - diagnosis; Lung Neoplasms - genetics; Lung Neoplasms - mortality; Male; Medical prognosis; Metastasis; MicroRNAs; MicroRNAs - blood; MicroRNAs - genetics; Middle Aged; Mortality; Protein expression; Retrospective Studies; serum mirna; survival; Survival Rate; 临床研究; Indonesia; Serum miRNA; Advanced stage NSCLC; Survival
• ISSN: 1009-3419; 1999-6187; 1999-6187
• DOI: 10.3779/j.issn.1009-3419.2020.104.02

Lung cancer is the most common cause of death in men in the world and in Indonesia where non-small cell carcinoma lung cancer (NSCLC) constitutes 85% of all lung cancer cases. The high mortality rate is due to a poor prognosis and is often diagnosed as having advanced stages. If it is known at the initial stage, the prognosis of lung cancer will be better. Prognosis can be predicted with a marker of prognostic biology, one of which is micro RNA (miRNA). This study aims to prove that serum miRNA can be predictive biological marker and prognosis in NSCLC patients in Indonesia. This study was cohort retrospective among 52 subjects in "Dharmais" Hospital National Cancer Center. Sample was obtained from patients' serum. MiR-34, miR-148, miR-155 and miR-222 serum are measured through Real-Time PCR (qPCR). Data were analyzed and interpreted with descriptive analysis, bivariate analysis (Mann Whitney-U for two type of variables or Kruskal-Wallis for more than two type of variables. Kaplan-Meier analysis was used to know association between characteristic which are sociodemographic, performance status, clinico-pathology, and survival rate in miRNA expression. From this study, miRNA expression: miR-34 (46.15%), miR-148 (23.08%), miR-155 (40.38%) and miR-222 (32.69%). Performance status score was statistically significant correlation with miR-148 (P=0.049) and miR-222 (P=0.018). High miR-34 is associated with multiple M1b metastatic type (P=0.020), cancer cell type (adenocarcinoma, P=0.009) and adenocarcinoma epidermal growth factor receptor (EGFR) mutation (negative, P=0.031). There was a significant correlation between the high miR-222 as a poor prognosis in advanced stage NSCLC with M1b metastasis (Median Survival/MS: 27 d, P=0.049) and positive EGFR mutations (MS: 74 d, P=0.049) and correlation of miR-155 with adenocarcinoma (MS: 69 d, P=0.034) and positive EGFR gene mutations (MS: 58 d, P=0.023). High miR-34 expression in advanced stage NSCLC is the predictive factor for multiple metastatic, adenocarcinoma cell type and adenocarcinoma negative EGFR mutation. High expression of miR-155 and miR-222 are poor prognoses, especially high miR-222 found in metastasis M1b and positive EGFR mutation and miR-155 found in adenocarcinoma and positive EGFR gene mutations. Further studies regarding correlation between miRNA and survival rate are needed.